Disclosures for "Successful Treatment of PML Due to Idiopathic CD4 Lymphocytopenia with Filgrastim after Pembrolizumab: A Case Report"
-
Dr. Dantu has nothing to disclose.
-
Dr. Dang has nothing to disclose.
-
Diane McLaughlin has received publishing royalties from a publication relating to health care.
-
Dr. Yoo has nothing to disclose.
-
Dr. Robers has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Robers has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG therapeutics. Dr. Robers has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Dr. Robers has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for TG Therapeutics. The institution of Dr. Robers has received research support from Bristol Myers Squibb Foundation.